secwatch.observer — SEC 8-K summary
======================================

Issuer:     AVANOS MEDICAL, INC. (AVNS)
CIK:        0001606498
Form:       8-K
Filed at:   2026-02-24T23:59:59+00:00
Accession:  0001606498-26-000002
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Avanos reports Q4 adjusted EPS $0.29 vs $0.43 prior year; FY2025 sales $701.2M up 1.9%
--------------------------------------------------------------------------------

- Q4 net sales $180.9M (+0.7% YoY); SNS segment up 8.7% to $115.1M; PM&R up 1.3% to $61.6M.
- Q4 GAAP net loss $1.3M ($0.03 loss per share); adjusted net income $13.4M ($0.29 adjusted EPS).
- Full-year 2025 net loss $72.9M; adjusted EBITDA $86.8M vs $107.6M in 2024.
- Recorded $77M non-cash goodwill impairment on PM&R segment in Q2 2025.
- 2026 guidance: net sales $700-720M; adjusted diluted EPS $0.90-1.10.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1606498/000160649826000002/0001606498-26-000002-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1606498/000160649826000002/avns-20260224.htm
  HTML page:      https://secwatch.observer/filing/0001606498-26-000002

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer